29 results
Thumbnail

D3.232 - The AhR agonist tapinarof suppresses human skin inflammation by inducing metabolic reprogramming and reducing production of mitochondrial pro-inflammatory DAMPs

Thumbnail

D3.231 - Gut Microbiome Dysbiosis in Antihistamine-Refractory Chronic Spontaneous Urticaria and Its Association with Disease Characteristics- A Cross-Sectional Case–Control Analysis

Thumbnail

D3.233 - Polypharmacy-Associated Lichenoid Eruption Simulating Keratosis Lichenoides Chronica

Thumbnail

D3.234 - Successful Use of Ritlecitinib in Long-Standing Alopecia Areata with Previous JAK Inhibitor Failure

Thumbnail

D3.235 - Trends in Sensitization to Preservatives and Epoxy Resins among occupationally exposed workers: A 31-Year Patch Test analysis from Tunisia

Thumbnail

D3.236 - Does Night Work Influence the Severity of Allergic Contact Dermatitis ?

Thumbnail

D3.237 - Specific Features of Allergic Contact Dermatitis in Diabetic Patients in a Dermato-Allergology Unit in Tunisia

Thumbnail

D3.238 - Allergic Contact Dermatitis to Formaldehyde: A 31-Year Experience in a Dermato-Allergology Consultation

Thumbnail

D3.239 - Foot Allergic Contact Dermatitis in Workers: Prevalence and Allergen Patterns

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project

Thumbnail

D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child

Thumbnail

D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD

Thumbnail

D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis